DGCRF Diagnocure Inc (CE)

QUEBEC CITY, April 9, 2013 /PRNewswire/ - In view of the annual and
special meeting of its shareholders on April 29, 2013, DiagnoCure Inc.
(TSX: CUR; OTCQX: DGCRF) (the "Corporation") announces the adoption by
its board of directors of an advance notice policy establishing
conditions and framework to submit director nominations, similar to
what is set forth in the advance notice by-law adopted on
March 11, 2013.

The advance notice by-law, which is fully described in the management
proxy circular filed on March 26, 2013 under the Corporation's profile
at www.sedar.com, requires advance notice to the Corporation in circumstances where
nominations of persons for election as a director of the Corporation
are made by shareholders other than pursuant to: (i) a requisition of a
meeting made pursuant to the provisions of the Business Corporations Act (Quebec); or (ii) a shareholder proposal made pursuant to the
provisions of this same act. Among other things, the advance notice
by-law fixes a deadline by which shareholders must submit a notice of
director nominations to the Corporation prior to any annual or special
meeting of shareholders where directors are to be elected and sets
forth the information that a shareholder must include in the notice for
it to be valid.

As an interim and special procedure before ratification of the advance
notice by-law by the shareholders, the policy stipulates that an
advance notice regarding nominations of directors will have to be sent
to the Corporation not less than 10 days prior to the upcoming meeting
of April 29, 2013, i.e. by April 18, 2013 at the latest (rather than
the 30 to 65 days prior to the date of the meeting required by the
advance notice by-law). All the other provisions of the advance notice
by-law which are described in the management proxy circular and
available under the Company's profile at www.sedar.com apply under the policy.

The policy on the advance notice is effective immediately. At the next
meeting of shareholders, shareholders will be asked to confirm and
ratify the advance notice by-law.

The Corporation believes the advance notice policy and the advance
notice by-law will facilitate orderly and efficient annual or special
meetings. The immediate implementation of the advance notice policy
adopted by the Corporation's board of director will allow the
Corporation and its shareholders to readily benefit from this good
corporate governance practice, allowing the Corporation's shareholders
to cast an informed vote, based on information on the proposed
nominees' qualifications and suitability as directors.

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. Previstage^TM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary
of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using PCA3,
DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the United States. For
more information, visit www.diagnocure.com.

Forward?looking statements

This release contains forward?looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward?looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward?looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward?looking statements contained herein unless required by the
applicable securities laws and regulations.

SOURCE DiagnoCure inc.